34 trends tracked about this subject — the full history, oldest to newest below.
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
Researchers have identified a way to utilize p53 activation to enhance the potency and longevity of immune cells targeting solid tumors.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A landmark trial reveals the first successful cancer vaccine, reducing the risk of melanoma recurrence or death by 42%.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna's cancer vaccine shows a 42% reduction in melanoma recurrence in Phase 3 trial data leaked prior to ESMO.
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
Moderna stock extends recent market losses following the release of trial data concerning a novel mRNA melanoma vaccine.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Personalized mRNA cancer vaccine data shows significant reduction in melanoma recurrence and death rates.
Moderna shares tumble following a reported leak of cancer vaccine data involving melanoma treatments.
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
Advances in personalized mRNA vaccines are showing promise in treating melanoma, though experts warn that misinformation may hinder their adoption.
Recent coverage examines the growing cancer vaccines market alongside Phase 3 mRNA vaccine results and personalised medicine strategies.
Moderna shares surge toward a 52-week high as upcoming melanoma vaccine data commands attention at the ESMO Congress.
14 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
Advancements in mRNA technology are driving the development of cancer vaccines, specifically targeting melanoma and expanding medical breakthroughs.
Moderna and Merck's mRNA melanoma vaccine is drawing significant attention as a potential game changer according to recent coverage.
Moderna shares double following clinical trial results for a personalized mRNA melanoma vaccine developed with Merck.
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
Moderna stock surges after a partnered melanoma vaccine developed with Merck successfully reduced cancer recurrence in a large-scale clinical trial.
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA cancer vaccine.
The FDA has granted accelerated approval to Replimune's melanoma drug Tudriqev following a yearlong regulatory clash.
Replimune shares surge following a favorable FDA advisory panel vote for its melanoma treatment.
Entertainment outlets report that William Shatner and his daughter Melanie battled stage 4 cancer.
Medical professionals and health authorities are urging the public to use specific checklists to identify potential melanoma and skin cancer signs this summer.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A doctor’s ABCDE checklist is sparking a wave of coverage on spotting skin‑cancer signs beyond ordinary moles